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Abstract
Background: The association between human papillomavirus (HPV) infection and non-melanoma skin cancers
(NMSCs) such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is not yet fully understood. We
analysed the prevalence and spectrum of cutaneous beta-HPV types and mucosal/genital HPV types in paired
biopsies (tumour and corresponding perilesional skin) obtained from 50 BCC immunocompetent patients. A small
group of SCC patients (n=9) was also included. We also evaluated some previously postulated risk factors for HPV
infection in NMSC patients.
Results: All biopsies were negative for mucosal/genital HPV types. Overall, beta-HPV DNA was detected more often
in SCC compared to BCC patients (78% vs 55% of total samples). The frequency of infection increased with the
patient’s age [OR=4.88 (95% CI 1.29-18.39)]. There was no significant correlation between beta-HPV positivity and
sex, skin type and UV exposure. The prevalence of beta-HPV species 1 types was significantly higher than those
belonging to other beta-HPV species in biopsies from BCC (p=0.022) but not from SCC subjects (p=0.091). There
was no significant difference in the overall prevalence of beta-HPV infection and the number of viral types between
tumour lesions and perilesional skin. BCC samples were significantly more likely to be infected with beta-HPV
species 1 types compared to perilesional skin (p=0.036) and showed a higher frequency of mixed infections
(p=0.028).
Conclusions: These findings demonstrate that beta-HPV types belonging to species 1 are the most common HPV
types detected in the skin of BCC patients. Moreover beta-1-HPV types and mixed infections are significantly more
frequent in tumour samples than in healthy perilesional skin. Our results suggest that beta-1-HPVs as well as
co-infection with more than one viral type could be important in NMSC and in particular in BCC.
Further studies aimed to compare the biological activity of viral types in tumours and in healthy skin (viral
replication and expression, interference of infection with cellular functions) are necessary to understand the role of
HPV infection in skin cancer.
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Background
Human papillomaviruses (HPVs) are highly prevalent in
the human population [1-3] and are classified as alpha,
beta, gamma, mu and nu genera [4]. Based on the fre-
quency of HPV-DNA detection in different kinds of
lesions, HPVs can be divided into cutaneous types com-
monly found in benign skin warts, mucosal types
detected in genital condylomas and anogenital cancers
and epideromodysplasia verruciformis (EV) types, now
indicated as beta-HPVs, which had initially been identi-
fied in warts and in skin carcinomas of EV patients [5].
The oncogenic role of some mucosal HPVs has been
demonstrated for a number of epithelial cancers of the
anogenital and upper respiratory tracts [6] while the etio-
logical relationship between specific HPV types and non-
melanoma skin cancers (NMSCs), such as squamous cell
carcinoma (SCC) and basal cell carcinoma (BCC) remains
unclear. A number of epidemiological studies have de-
monstrated the association between markers of beta-HPV
infection and SCC in EV patients [7] and in organ trans-
plant recipients [8-10]. There is accumulating evidence
that beta-HPVs may play a role in the pathogenesis of
NMSC also in the general, immunocompetent population
[11-13]. The mechanisms by which beta-HPVs may play
a role in carcinogenesis have yet to be established. One
possible hypothesis is that beta-HPVs may impair host
cell defences against excessive sun light exposure, thus
interfering with DNA repair and apoptosis [14-16]. A
lower viral load in tumour tissues than in precursor
lesions such as actinic keratosis (AK) supports the “hit
and run” hypothesis according to which the virus plays a
role in early stages of carcinogenesis and is not necessary
for the maintenance of the malignant phenotype [17].
The majority of studies on the role of HPV in NMSCs,
so far, have focused on squamous cell carcinomas
whereas there are a limited number of reports regarding
HPV infection in basal cell carcinomas. BCC is the most
common skin cancer and, in recent years, its incidence
has increased worldwide [18,19]. The major risk factor
for BCC is exposure to ultraviolet radiation (UVB) in
individuals with susceptible skin type as well as a specific
genetic background [20-22]. The role of HPV infection
in the pathogenesis of BCC is poorly understood.
In the present study we analysed paired biopsies
(tumour and adjacent skin) obtained from 50 BCC im-
munocompetent patients. A small group of SCC patients
(n=9) was also included. The comparison between HPV
infection pattern in tumour and in perilesional skin
obtained from the same subject, and thus characterized
by the same variables that influence skin cancer risk,
seems to be a very good approach for assessing a pos-
sible correlation between HPV and tumours. We also
evaluated some previously postulated risk factors for
HPV infection in NMSC patients.
Results
HPV prevalence and spectrum in NMSC patients
Overall beta-HPV infection was detected in 69 out of
118 (58%) samples. The infection was found to be more
prevalent in samples from SCC patients [14 out of 18
(78%)] in comparison to BCC patients [55 out of 100
(55%)], however this difference did not reach statistical
significance (p=0.058) (Table 1). The number of positive
samples detected using the RHA Kit Skin (beta) HPV
corresponded to that obtained by the nested FAP-PCR.
All specimens that tested negative for HPV DNA were
positive for human beta-globin DNA, indicating that
these samples contained DNA of sufficient quantity and
quality for PCR amplification. All biopsies resulted nega-
tive for mucosal/genital HPVs.
Forty-four out of 59 (75%) patients harboured beta-
HPV DNA in tumour and/or in perilesional skin. Thirty-
five out of 50 (70%) BCC patients and 9 out of 9 (100%)
SCC patients resulted positive at tumour and/or at peri-
lesional skin. There was no statistically significant differ-
ence with regard to HPV prevalence between SCC and
BCC patients (p=0.056).
In the analysed samples we detected beta-HPV types
belonging to species 1 (HPV5, 8, 12, 14, 19, 20, 21, 24,
25, 36, 47, 93, 105), species 2 (HPV9, 15, 17, 23, 37, 38,
80, 100), species 3 (HPV49), species 4 (HPV92), and
some previously described putative unclassified types
(FA7, FA14, FA108, FA114.2, FA118, FA149, FAIMVS6.4,
FAIMVS7). The most prevalent types (HPV5, 8, 24 and
HPV93), all belonging to the beta-HPV species 1, were
present in 18%, 10%, 15%, and 10% of total samples re-
spectively. HPV types 5, 8 and 93 were found in both
tested groups whereas HPV24 was present in samples
from BCC patients only.
Viral types within beta-HPV species 1 were signifi-
cantly more common, found in 60 out of 118 (51%)
samples, in comparison to those belonging to other
beta-HPV species which were detected in 40 out of 118
(34%) biopsies (p=0.006) (Table 2). Among biopsies
obtained from BCC patients beta-1-HPV types were sig-
nificantly more frequent [48 out of 100 (48%) samples]
than other beta-HPV types [33 out of 100 (33%) samples]
(p=0.022). Among biopsies obtained from SCC patients
beta-1-HPV types were more frequent [12 out of 18
(67%) samples] than other beta-HPV types [7 out of 18
(39%) samples] but this difference did not reach statis-
tical significance (p=0.091).
Forty-four out of 118 (37%) samples harboured more
than one genotype. There was no statistically significant
difference with regard to the prevalence of mixed infec-
tions between samples from BCC and SCC patients [34
out of 100 (34%) vs 10 out of 18 (56%); p=0.072] (Table 2).
The frequency of beta-HPV infection in the studied
population increased with the patient’s age when adjusted
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for sex, skin type and UV exposure (OR=4.88 [95% CI,
1.29-18.39]) (Table 3). When analysis was performed
separately for BCC patients the adjusted OR was 4.6
[95% CI, 1.1-18.3]. There was no significant correlation
between beta-HPV positivity and sex, skin type and UV
exposure.
Comparison between NMSC and perilesional skin biopsies
Beta-HPV DNA was detected more often in tumours
[39 out of 59 (66%)] than in perilesional skin [30 out of
59 (51%)], however this difference did not reach statis-
tical significance (p=0.067). Thirty-one out of 50 (62%)
BCC samples and 24 out of 50 (48%) corresponding
perilesional skin biopsies tested beta-HPV positive and
among samples obtained from SCC patients 8 out of 9
(89%) tumours and 6 out of 9 (67%) paired perilesional
skin resulted beta-HPV positive (Table 1). No statisti-
cally significant difference in HPV prevalence was
observed between tumours and perilesional skin from
BCC (p=0.114) and from SCC patients (p=0.288).
Among 59 tumor/perilesional skin biopsy pairs 15
(25%) were HPV negative, 19 (32%) patients were posi-
tive only at tumour or at perilesional skin while 25
(42%) had beta-HPV DNA in both biopsies. In 2 patients
the viral types in tumours were different from those
detected in perilesional skin, 3 patients had identical
HPV types in both biopsies and in 20 patients one or
more identical HPV types were detected in tumours and
in corresponding healthy skin.
Among the most prevalent types, HPV5, 8 and 93
were uniformly distributed between tumours and perile-
sional skin samples while HPV24 was twice as frequent
in BCC than in corresponding perilesional skin. No par-
ticular beta-HPV types were significantly associated
tumours or with healthy tissue (Figure 1).
Thirty-six out of 59 (61%) tumours tested positive for
beta-1-HPV types compared with 23 out of 59 (39%)
tumours positive for other beta-HPV types. This differ-
ence was statistically significant (p=0.013) (Table 2).
Viral types belonging to species 1 were significantly
more frequent in tumours than in perilesional skin [36
out of 59 (61%) vs 24 out of 59 (41%); p=0.021]. More-
over the prevalence of beta-1-HPV in samples from
BCC patients was significantly higher than the preva-
lence of other beta-HPV types [29 out of 50 (56%) vs 18
out of 50 (36%); p=0.022] and was also significantly
higher in tumours than in perilesional skin [29 out of 50
(56%) vs 19 out of 50 (38%); p=0.036].
Table 1 Prevalence of human beta-papillomavirus (beta-HPV) in NMSC and in perilesional skin biopsies in
immunocompetent patients
Diagnosis Tumour biopsy Perilesional skin Total
No. of positive/total (%) No. of positive/total (%) No. of positive/total (%)
BCC 31/50 (62) 24/50 (48) 55/100 (55)
SCC 8/9 (89) 6/9 (67) 14/18 (78)
Total 39/59 (66) 30/59 (51) 69/118 (58)
NMSC: non-melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma.
Table 2 Prevalence of beta-HPV species and frequency of multiple infections in tumour and in perilesional skin
samples from NMSC immunocompetent patients
Diagnosis Tumour biopsy Perilesional biopsy Total
No. of positive/total (%) No. of positive/total (%) No. of positive/total (%)
Beta1-HPV
BCC 29/50 (56) 19/50 (38) 48/100 (48)
SCC 7/9 (76) 5/9 (56) 12/18 (67)
Total 36/59 (61) 24/59 (41) 60/118 (51)
Other than beta1-HPV
BCC 18/50 (36) 15/50 (30) 33/100 (33)
SCC 5/9 (56) 2/9 (22) 7/18 (39)
Total 23/59 (39) 17/59 (29) 40/118 (34)
Multiple infection
BCC 22/50 (44) 12/50 (24) 34/100 (34)
SCC 6/9 (67) 4/9 (22) 10/18 (56)
Total 28/59 (47) 16/59 (27) 44/118 (37)
NMSC: non-melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma.
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Infections with multiple HPV types was found to be
significantly more common in tumours [28 out of 59
(47%)] than in perilesional skin [16 out of 59 (27%)]
(p=0.018). Mixed infections were detected in 22 out of
50 (44%) BCC samples compared with 12 out of 50 (24%)
of corresponding perilesional skin biopsies. This differ-
ence was statistically significant (p=0.028) (Table 2).
Viral load determination by real-time PCR for HPV5
and HPV24 revealed low HPV DNA levels, frequently
below the detection limit of quantitative PCR, both in
tumour and in perilesional skin biopsies. In samples
with quantifiable DNA levels the viral loads ranged from
1 viral copy per 12,000 cell equivalents to 1 copy per
0.01 cell equivalents (100 HPV DNA copies per 1 cell
equivalent). The comparison of HPV5 DNA level in
tumour and perilesional skin obtained from 3 patients
revealed a 20–50 times higher viral load in tumours than
in perilesional skin. On the other hand, HPV24 DNA
level was 20–60 times higher in perilesional skin than in
tumour samples obtained from 4 patients (Table 4).
Discussion
The overall beta-HPV positivity in the tested population
was high since 70% of BCC patients had viral DNA
detected in the tumour and/or perilesional skin. A
higher prevalence of infection (100%) was observed in
the SCC group, but this did not reach statistical signifi-
cance. All samples were negative for the high risk and
low risk HPV DNA screening and genotyping test able
to detect 28 main mucosal/genital HPV types. This
could underscore the propensity of certain HPV types to
infect and replicate preferentially in either mucosal or
cutaneous epithelium and is in line with some previous
studies, where the mucosal types were not found at all
or only rarely either in tumour or normal skin samples
[8,9,23,24]. On the other hand, the findings of Iftner and
colleagues [25] have suggested that persistent infections
of the skin with some high risk genital HPV types such
as HPV16, 31, 35 and 59 may be a risk factor for NMSC
in the immunocompetent population. These discrepan-
cies between results obtained in different investigations
could reflect differences in sensitivity and/or specificity
of detection methods used by various authors as well as
differing characteristics of patients included in the stud-
ies. Since the commercial test used in our study is highly
sensitive and specific we can conclude that genital HPV
types, if present, are extremely rare in the skin disorders,
which were the subject of the present study.
Table 3 Risk factors for cutaneous human papillomavirus
infection in NMSC subjects
HPV status













Female 16/22 3/3 19/25
Male 19/28 6/6 25/34 1.11 (0.30-4.05)
Age
48-70 7/15 1/1 8/16
71-99 28/35 8/8 36/43 4.88 (1.29-18.39)
Skin type
3 23/34 4/4 27/38
2 12/16 5/5 17/21 0.82 (0.20-3.37)
UV exposure
Low 18/27 7/7 25/34
Moderate/high 17/23 2/2 19/25 0.59 (0.16-2.10)
NMSC: non-melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous
cell carcinoma.
a OR values were calculated for the total (no.= 44) positive subjects and










Figure 1 Comparison of the spectrum and prevalence of beta-HPV types in BCC and in perilesional skin biopsies. The percentage of
positive samples harbouring each beta-HPV type/putative type is illustrated. Many biopsies contained more than one HPV type.
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We observed that increasing age was associated with a
higher prevalence of beta-HPV infection in our studied
population. This observation is in line with some data
reported in the literature [3] and may be the conse-
quence of the natural deterioration of the immune sys-
tem which could facilitate both viral infection and
reactivation in elderly individuals. There was no signifi-
cant correlation between beta-HPV positivity and sex,
skin type and UV exposure.
We found no significant differences in HPV prevalence
between tumours and perilesional skin samples. How-
ever, viral DNA was detected more often in both BCC
and SCC than in corresponding perilesional skin biop-
sies. These findings are in line with some previous stud-
ies in which the prevalence of HPV infection in both
kinds of tumours was slightly higher than in adjacent
perilesional [24,26]. The detection rate of HPV DNA in
tumour samples analysed in our study falls within the
value range reported in other investigations [13,23]. It is
also higher than the frequency of beta-HPV detection in
normal skin from healthy subjects [25,27].
We found that beta-1-HPV types were significantly
more common than types belonging to other beta-HPV
species (p=0.006) in our studied population. This was
also observed in the case of samples from BCC
(p=0.022) but not from SCC patients. The most preva-
lent types (HPV5, 8, 24 and 93) identified in samples
from BCC patients accounted for 41% (54 out of 133) of
total infections. HPV24 was never detected in SCC sam-
ples and the most prevalent types (HPV5, 8 and 93)
represented 26% (9 out of 34) total infections. Some lit-
erature data indicate that beta-HPV species 2 is more
likely to be identified in SCC than in perilesional healthy
skin [23,26]. In another study beta-HPV species 1 types
were detected more often in SCC than in BCC biopsies
[13]. In the present investigation we mainly analysed
paired tumour and perilesional skin biopsies from BCC
patients. Only a limited number of samples from SCC
individuals was included. We found that the genotypes
belonging to species 1 were statistically more common
in tumours than in perilesional skin from the overall
studied population (p=0.021) and this was also the case
with BCC patients alone (p=0.036).
The prevalence of mixed infections was found to be
high since 44 out of 69 (64%) positive samples har-
boured more than one beta-HPV type. Multiple infec-
tions were more common in samples from SCC patients
(56%) compared to samples from BCC patients (34%) al-
though this difference was not statistically significant.
Mixed infections were significantly higher in tumours
than in perilesional skin (p=0.018) of the overall studied
population and of BCC patients alone (p=0.028).
Twenty-five out of 44 beta-HPV positive patients
(57%) harboured HPV infection in both biopsies whereas
19 (43%) patients had only positive tumour or perile-
sional samples.
There was no significant difference in the number of
viral types between tumours and adjacent skin. We
observed a high degree of overlap between the beta-
HPV types in paired biopsies as the viral types found in
tumours were completely different from those present in
perilesional skin from the same patients in only in 2 out
of 25 cases. Our results differ somewhat from the find-
ings of a study of HPV prevalence and spectrum in SCC
patients carried out by Plasmeijer and collaborators [28].
In this study quite a similar median number of beta-
HPVs was found in perilesional skin and SCC tissue, but
a different spectrum of viral types was seen. The authors
hypothesized that the types present in the perilesional
skin could partially represent commensal types, whereas
those in the tumour could be associated with SCC for-
mation. In agreement with previous studies [24,28] we
found that no single type prevailed in NMSC and/or in
perilesional skin in immunocompetent individuals.
Moreover, HPV24 was twice as frequent in BCC than in
perilesional skin.
A number of studies report the prevalence and distri-
bution of HPV types in NMSCs, in benign lesions and in
perilesional skin but there are limited data regarding the
rate of replication and expression of different beta-HPVs
in different kinds of lesions. It cannot be excluded that
different beta-HPVs may exhibit different rates of repli-
cation and/or different expression patterns in different
types of lesions such as tumour and normal perilesional
skin. A comparison of HPV DNA loads in NMSC and in
corresponding adjacent skin described in previous stud-
ies [24,29] did not reveal the tendency to differ. Interest-
ingly a comparison of viral load in a limited number of
paired biopsies both positive for HPV5 or for HPV24,
carried out in our study, might suggest a varying replica-
tive activity of two viral types in two different kinds of
samples.
Further studies need to be performed to investigate
the biological activity of viral types detected in paired
Table 4 Viral load determination for HPV5 and HPV24 in
paired samples (tumour and corresponding perilesional
skin)
Patient 1 HPV5 copy/no. of cell Patient 1 HPV24 copy/no. of cell
equivalents1 equivalents1
BCC Perilesional skin BCC Perilesional skin
1 61 1200 4 75 2.3
2 1 50 5 6410 107
3 132 3566 6 641 32
- - - 7 932 22
1 The viral loads were corrected for the input amount cells as described in
“Material and methods”.
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biopsies. It can be useful to determinate viral load, viral
gene expression and the interference of HPV infection
with cellular gene expression in tumours and in healthy
skin to understand the role of HPV infection in skin
cancers. A recent study has demonstrated that the up-
regulation of p16INK4a and AKT/P13K pathway in BCC
is often associated with the presence of beta-HPV spe-
cies 2 suggesting, that in a subtype of BCC these viruses
may exert a role in the carcinogenesis or in other, still
undefined, biological property of these tumours [30].
Conclusions
In summary, the overall prevalence of beta-HPV was
higher in SCC than in BCC patients. No mucosal/genital
HPV types were detected. Beta-HPV types belonging to
species 1 represented the most common infection de-
tectable in NMSC, and in particular, in the BCC popula-
tion. The most common types detected in samples from
the BCC patients (HPV5, 8, 24 and 93) accounted for
41% of total infections. The tumour lesions did not seem
to differ significantly from perilesional skin with regard
to the overall prevalence of beta-HPV infection and the
number of viral types detected in paired biopsies. How-
ever beta-HPV types from species 1 were significantly
more frequent in BCC samples which were also charac-
terized by a higher frequency of multiple infections. Our
results suggest that beta-1-HPVs as well as co-infection
with more than one viral type could be important in
NMSC and in particular in BCC.
Material and methods
Patients
All procedures followed were approved by appropriate
Ethics Committee related to our institutions (Azienda
Sanitaria di Firenze, Università di Firenze, Firenze, Italy).
Research was carried out in accordance with Helsinki
Declaration. All patients were recruited after written,
informed, consent. Fifty-nine patients, 25 female and 34
male, referred to the Dermatology Clinic at the University
of Florence for the removal of suspected NMSCs were
studied. All patients were immunocompetent (mean age
75.7 years, range 48–99). None of the patients was recei-
ving immunosuppressive or immunostimulating drug
therapy.
Samples
Punch biopsies were collected from both the tumour and
perilesional skin (roughly 1 cm away from the lesional
border) from each patient. The samples were immersed
in RNAlater RNA Stabilization Reagent (Qiagen) and
conserved at −20°C. The remaining tumour was excised
and sent for histopathological diagnosis.
Overall, 50 BCC patients and 9 SCC patients were
included in this study. The samples were classified on
the basis of skin type (II-III, according to the Fitzparick
classification [31]). The level of sun exposure at the site
of biopsy was classified, by a single dermatologist, into
three categories based on anatomical site: extensive (i.e.,
head and neck), moderate (i.e., trunk and extremities),
or low (i.e., buttocks and genital area).
Nucleic acids extraction
The DNA was extracted from each sample using All
Prep DNA/RNA Mini Kit (Qiagen) and stored at −70°C.
The quality of isolated DNA was checked by PCR ampli-
fication of the human beta-globin gene [32].
Beta-HPV DNA detection and typing
To maximize the reliability and sensitivity of analysis,
the samples were tested by two different methods. First
the two-step version of the nested FAP-PCR with degen-
erated primers was performed. This PCR yielded a 235-
base pair fragment corresponding to part of an L1 gene
and is able to amplify more than 20 known HPV types,
mainly beta-HPVs [33]. The PCR products were purified
using DNA gel extraction kit (Millipore) and cloned
using a pGEM-T Easy Vector System (Promega). At least
2 clones per sample were purified using QIAprep Spin
Miniprep Kit (Qiagen) and sequenced according to the
manual of the Big Dye Terminator Cycle Sequencing kit
using the ABI310 sequencer (Applied Biosystems). The
sequencing reaction was performed using primers flank-
ing the plasmid cloning region: forward primer T7 5’-
TAA TAC GAC TCA CTA TAG GG and reverse primer
Sp6 5’-TAT TTA GGT GAC ACT ATA G. For genotyp-
ing the DNA sequences were compared with those
already available in GenBank database, by using the
BLAST server (http://blas.ncbi.nlm.nih.gov//Blast.cgi).
Subsequently HPV detection and genotyping were car-
ried out using the RHA Kit Skin (beta) HPV (Diassay,
Rijswijk, the Netherlands). This method was designed
for the amplification and typing of 25 beta-HPV types.
Briefly, a broad spectrum PCR using biotinylated con-
sensus primers was used to amplify a 117-base pair re-
gion from the E1 gene. The biotinylated amplicons were
subsequently hybridized with specific oligonucleotide
probes immobilized as parallel lines on membrane strips.
The bands were then analyzed against a reference sheet.
The necessary precautions to avoid contamination be-
tween samples were observed during all steps of sample
handling and, in each PCR run, water samples and
known HPV negative specimens were included as nega-
tive controls.
Mucosal/genital HPV detection
All samples were analysed by INNO-LiPA HPV Geno-
typing Extra (Innogenetics, Italy) according to the manu-
facturer’s instructions. INNO-LiPA HPV Genotyping
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Extra is a line probe assay, based on the reverse
hybridization principle, designed for the identification of
28 different genotypes of the human papillomavirus by
detection of specific sequences in the L1 region of the
HPV genome. The assay covers all currently known
high-risk HPV genotypes and probable high-risk HPV
genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, 73, 82) as well as a number of low-risk
HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some add-
itional types (69, 71, 74).
Statistical analysis
Stata software was used to analyse the data by logistic
regression analysis. Fisher’s exact test was used for ana-
lysis of the differences in distribution of HPV prevalence
among groups. A P<0.05 was considered to be statisti-
cally significant.
HPV DNA quantification
Type-specific real time PCR protocols described previ-
ously [34] were used for HPV5 and 24 DNA quantifica-
tion. To check for PCR efficiency and DNA integrity
and to determine the number of input cell equivalents,
the beta-globin gene was quantified. The HPV DNA
loads were defined as 1 HPV DNA copy per number of
cell equivalents. Two beta-globin gene copies were taken
as a cell equivalent. Some negative controls (total cellu-
lar DNA) were included in each run.
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